Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1972 1
1976 3
1978 1
1980 2
1981 3
1982 1
1983 2
1984 5
1985 11
1986 9
1987 9
1988 22
1989 15
1990 32
1991 22
1992 42
1993 44
1994 82
1995 62
1996 54
1997 53
1998 76
1999 85
2000 55
2001 150
2002 68
2003 82
2004 85
2005 103
2006 93
2007 126
2008 133
2009 127
2010 142
2011 178
2012 202
2013 219
2014 195
2015 197
2016 213
2017 293
2018 233
2019 230
2020 318
2021 260
2022 285
2023 241
2024 106

Text availability

Article attribute

Article type

Publication date

Search Results

4,539 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Immunodeficiency 75"
Page 1
Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.
Stohl W, Schwarting A, Okada M, Scheinberg M, Doria A, Hammer AE, Kleoudis C, Groark J, Bass D, Fox NL, Roth D, Gordon D. Stohl W, et al. Arthritis Rheumatol. 2017 May;69(5):1016-1027. doi: 10.1002/art.40049. Epub 2017 Apr 7. Arthritis Rheumatol. 2017. PMID: 28118533 Free PMC article. Clinical Trial.
OBJECTIVE: To assess the efficacy and safety of subcutaneous (SC) belimumab in patients with systemic lupus erythematosus (SLE). METHODS: Patients with moderate-to-severe SLE (score of 8 on the Safety of Estrogens in Lupus Erythematosus National Assessment [SELENA] version …
OBJECTIVE: To assess the efficacy and safety of subcutaneous (SC) belimumab in patients with systemic lupus erythematosus (SLE). METHODS: Pa …
Women and AIDS.
Schuman P, Sobel JD. Schuman P, et al. Aust N Z J Obstet Gynaecol. 1993 Nov;33(4):341-50. doi: 10.1111/j.1479-828x.1993.tb02106.x. Aust N Z J Obstet Gynaecol. 1993. PMID: 8179538 Review.
The number and proportion of women infected with the human immunodeficiency virus (HIV) and with the acquired immunodeficiency syndrome (AIDS) have increased rapidly throughout the last decade. ...More than 50% of US women with AIDS live in New York City, Newark, Ba …
The number and proportion of women infected with the human immunodeficiency virus (HIV) and with the acquired immunodeficiency …
Pathophysiological mechanism of non-HIV Pneumocystis jirovecii pneumonia.
Asai N, Motojima S, Ohkuni Y, Matsunuma R, Nakashita T, Kaneko N, Mikamo H. Asai N, et al. Respir Investig. 2022 Jul;60(4):522-530. doi: 10.1016/j.resinv.2022.04.002. Epub 2022 Apr 29. Respir Investig. 2022. PMID: 35501264 Review.
While Pneumocystis jirovecii pneumonia (PCP) can occur in immunocompromised patients with HIV infection, the prognosis of non-HIV PCP is still poor, showing a high mortality rate of 30%-75%. The pathophysiological mechanism of non-HIV PCP is quite different from that of HI …
While Pneumocystis jirovecii pneumonia (PCP) can occur in immunocompromised patients with HIV infection, the prognosis of non-HIV PCP is sti …
Acquired immune deficiency syndrome in childhood.
Shannon KM, Ammann AJ. Shannon KM, et al. J Pediatr. 1985 Feb;106(2):332-42. doi: 10.1016/s0022-3476(85)80320-6. J Pediatr. 1985. PMID: 2982008 Review.
The acquired immunodeficiency syndrome has been observed with increasing frequency in children with associated hemophilia, high-risk environmental backgrounds, and blood transfusions. ...The average age of 36 US child AIDS victims studied in detail was 5 months at p …
The acquired immunodeficiency syndrome has been observed with increasing frequency in children with associated hemophilia, hig …
Tuberculosis treatment and resulting abnormal blood glucose: a scoping review of studies from 1981 - 2021.
Williams V, Onwuchekwa C, Vos AG, Grobbee DE, Otwombe K, Klipstein-Grobusch K. Williams V, et al. Glob Health Action. 2022 Dec 31;15(1):2114146. doi: 10.1080/16549716.2022.2114146. Glob Health Action. 2022. PMID: 36178364 Free PMC article. Review.
RESULTS: Of the 1,277 articles extracted, 14 were included in the final review. All the studies were observational and 50% were prospective. Fasting blood sugar was the most common clinical test (64%), followed by the glycated haemoglobin test and the oral glucose toleranc …
RESULTS: Of the 1,277 articles extracted, 14 were included in the final review. All the studies were observational and 50% were prosp …
Performance of Cardiovascular Risk Prediction Models Among People Living With HIV: A Systematic Review and Meta-analysis.
Soares C, Kwok M, Boucher KA, Haji M, Echouffo-Tcheugui JB, Longenecker CT, Bloomfield GS, Ross D, Jutkowtiz E, Sullivan JL, Rudolph JL, Wu WC, Erqou S. Soares C, et al. JAMA Cardiol. 2023 Feb 1;8(2):139-149. doi: 10.1001/jamacardio.2022.4873. JAMA Cardiol. 2023. PMID: 36576812 Free PMC article.
MAIN OUTCOMES AND MEASURES: Measures of calibration and discrimination. RESULTS: Nine unique observational studies involving 75 304 people (weighted average age, 42 years; 59 490 male individuals [79%]) living with HIV were included. ...Included in the study were cu …
MAIN OUTCOMES AND MEASURES: Measures of calibration and discrimination. RESULTS: Nine unique observational studies involving 75 …
Multifactorial immunodeficiency in frail elderly patients: Contributing factors and management.
Tannou T, Koeberle S, Manckoundia P, Aubry R. Tannou T, et al. Med Mal Infect. 2019 May;49(3):167-172. doi: 10.1016/j.medmal.2019.01.012. Epub 2019 Feb 16. Med Mal Infect. 2019. PMID: 30782449 Review.
Immunodeficiency in the elderly is multifactorial. The analysis of etiological factors demonstrates the major role of immunosenescence and protein-energy malnutrition (PEM) with high prevalence deficiencies in micronutrients such as vitamin D, zinc, or vitamin E in people …
Immunodeficiency in the elderly is multifactorial. The analysis of etiological factors demonstrates the major role of immunosenescenc …
Expanding TREC and KREC Utility in Primary Immunodeficiency Diseases Diagnosis.
Korsunskiy I, Blyuss O, Gordukova M, Davydova N, Zaikin A, Zinovieva N, Zimin S, Molchanov R, Salpagarova A, Eremeeva A, Filipenko M, Prodeus A, Korsunskiy A, Hsu P, Munblit D. Korsunskiy I, et al. Front Immunol. 2020 Mar 3;11:320. doi: 10.3389/fimmu.2020.00320. eCollection 2020. Front Immunol. 2020. PMID: 32194560 Free PMC article.
A total of 434 children [189 healthy, 97 with group I and II PID (combined T and B cell immunodeficiencies & well-defined syndromes with immunodeficiency) and 148 group III PID (predominantly antibody deficiencies)] were included. Area under the curve (AU …
A total of 434 children [189 healthy, 97 with group I and II PID (combined T and B cell immunodeficiencies & well-defined synd …
HIV Risk and Pre-Exposure Prophylaxis Eligibility Among Emergency Department Patients.
Haukoos JS, White DAE, Rowan SE, Lyle C, Gravitz S, Basham K, Godoy A, Kamis K, Hopkins E, Anderson E. Haukoos JS, et al. AIDS Patient Care STDS. 2021 Jun;35(6):211-219. doi: 10.1089/apc.2021.0012. AIDS Patient Care STDS. 2021. PMID: 34097464 Free PMC article.
Our objective was to estimate the prevalence of pre-exposure prophylaxis (PrEP) eligibility, characterize self-perceived and quantified human immunodeficiency virus (HIV) risk, and assess PrEP knowledge and receptiveness of initiating PrEP among emergency department (ED) p …
Our objective was to estimate the prevalence of pre-exposure prophylaxis (PrEP) eligibility, characterize self-perceived and quantified huma …
Intravenous immunoglobulin therapy for HIV-associated Guillain-Barré syndrome.
Wang J, Zhang Y, Wang M, Ren Y, Tang M, Liu L, Zhou D. Wang J, et al. Int Immunopharmacol. 2022 Nov;112:109192. doi: 10.1016/j.intimp.2022.109192. Epub 2022 Sep 22. Int Immunopharmacol. 2022. PMID: 36155283
Patients treated with ART alone were compared with those treated with IVIG + ART. The primary outcome was the GBS disability score at 4 weeks, which was assessed with multivariable ordinal regression. Additional outcomes include the GBS disability scale at 1 week, improvem …
Patients treated with ART alone were compared with those treated with IVIG + ART. The primary outcome was the GBS disability score at …
4,539 results